Voyager Therapeutics Announces Longer-Term Data from Ongoing Phase 1b Trial for Advanced Parkinson’s Disease

[Farooqji]

Robust and durable improvements in patients' motor function achieved with substantial reductions in use of daily oral levodopa and other Parkinson’s disease medications; one-time administrations of VY-AADC well-tolerated now out to three years in Cohort 1

In Cohort 2 at 18 months, patients had a mean increase of five hours a day of on-time without any dyskinesia and experienced 65% less off-time, making this the likely dose for the pivotal Phase 2-3 program that remains on track to dose the first patient mid-2018

globenewswire.com/news-rele...

[saraoutwest]

Exciting!

[Juliegrace]

Interesting. Especially as the average age was relatively low for a PD study. Most would be young onset.

[Farooqji]

some more details

scienceofparkinsons.com/201...

[Farooqji]

According to Simon (owner of the scienceofparkinson.com) , the approach that Voyager Therapeutics is trialling here will not cure Parkinson’s, but it may make life a lot easier for those affected by it.